𝗢𝗻𝗰𝗼𝗱𝗲 𝗜𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗲, 𝗢𝗻𝗰𝗼𝗱𝗲 𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗼𝗿 𝗮𝗻𝗱 𝗖𝗮𝗻𝗰𝗲𝗿 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗛𝗼𝗿𝗶𝘇𝗼𝗻𝘀 𝗳𝗼𝗿𝗺 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗮𝗹𝗹𝗶𝗮𝗻𝗰𝗲 𝗱𝘂𝗿𝗶𝗻𝗴 𝗗𝘂𝘁𝗰𝗵 𝗲𝗰𝗼𝗻𝗼𝗺𝗶𝗰 𝗺𝗶𝘀𝘀𝗶𝗼𝗻 We are excited to announce that during this week's Dutch Economic Mission to the United Kingdom led by the Netherlands Enterprise Agency (RVO), The Dutch Ministerie van Buitenlandse Zaken, and the Dutch embassy in London, Oncode Institute, Oncode Accelerator, and Cancer Research Horizons – the innovation arm of Cancer Research UK (CRUK) – took an important step towards future collaboration. “Jan Paul Medema, our Scientific Director and Head of Oncode Institute: “Together we are stronger: with the vast pool of oncology expertise embodied by the partner’s commitment to building and funding innovations that accelerate the development of novel cancer therapies, we can further accelerate the translation of scientific breakthroughs to tangible solutions that benefit patients. This brings us closer to outsmarting cancer and impacting lives on an international scale.” Read the whole story here 👇 https://lnkd.in/gnSxkVx7 #OutsmartingCancer | #ImpactingLives Photo credits: pdmedia (https://lnkd.in/g9rEc3Qq)
Oncode Institute’s Post
More Relevant Posts
-
Introducing the #S3EStart Research Projects 🌟 OncoMets 🦾 The solution: An in vitro diagnostic tool for #BreastCancer monitoring, driven by a ground-breaking circulating biomarker discovery platform. Unlike invasive tumour biopsy and radiation-based methods, ONCOSECRET will provide accurate, non-invasive, real-time monitoring, enabling #EarlyDetection and reducing mortality rates. Easily integrated into #HealthcareSystems, it will empower #Oncologists to combat breast cancer effectively. 🧑🔬 The research team: Ana Sofia Ribeiro, Joana Paredes, Rita Pereira de Carvalho, Inês Sousa Conde, Bruno Freitas and Bárbara Macedo. 🔬 The institutions involved: i3S - Instituto de Investigação e Inovação em Saúde OncoMets is one of the 14 projects selected to participate in the 2024 edition of S3E Start, the EU-funded program fostering deep tech research and entrepreneurship in Southern Europe. It’s led by HiSeedTech, funded by European Innovation Council and SMEs Executive Agency (EISMEA) and officially recognised by EIT Deep Tech Talent. 🤝 This team is being supported by S3E Start mentors António Dinis. Don't forget to join us for the Start Open Day! Access the livestream on 18 June and watch all the teams present their science-based tech projects live from Lisbon 🚀 https://lnkd.in/ec5yyMzY #EUfunded #DeepTech #DeepTechInnovation #FromLabToMarket #HealthTech #HealthcareInnovation
-
🌟 Exciting News from SYNTHEMA! 🌟 This past Friday, 19th April, SYNTHEMA was thrilled to host the second meeting for the sister projects funded under the HORIZON-HLTH-2022-IND-13-02 call. The team is now preparing to launch a synergetic and coordinated effort to deliver more impact and increase awareness about the technologies employed and results achieved by each project. First step? Name, branding, colors! To make this recognizable across channels and networks. 🚀 Breaking Down Data Silos Our mission is clear: leverage cutting-edge technologies, we aim to enhance healthcare services and make significant strides towards more accessible and efficient patient care. 🤝 A Heartfelt Thank You We extend our deepest gratitude to all the projects that participated in this landmark event: EMERALDS NearData Consortium Phase4AI-EUProject SECURED EU project FLUTE Project - AI & Prostate Cancer PHEMS AISym4MED - Horizon Europe Your contributions and commitment to this cause are invaluable. We eagerly look forward to the advancements we will achieve together and the impact we will have on healthcare worldwide. #HealthcareInnovation #EuropeanCommission #AI #FederatedLearning #HealthcareTechnology #Collaboration #FutureOfHealthcare #horizoneurope
-
-
🌟 Congratulations to our portfolio company Verinnogen on its Innovate UK grant! The grant will support its collaboration with the National Physical Laboratory (NPL) to optimise its 3D surface profiling technology, designed to measure grafted tumours in preclinical cancer models more accurately, precisely, and quickly than traditional methods. Find out more below ⬇ #OnMyHorizon #Oncology Cancer Research Horizons
🎉 We are delighted to announce that Verinnogen has been successful in its application to Innovate UK’s Analysis for Innovators programme. After submitting our vision for key design areas within our novel tumour measuring tool, Innovate UK facilitated matchmaking with the world-leading National Physical Laboratory (NPL). Using their deep expertise, we will work together to optimize the optical configuration of this next generation tool, helping to bring fast, precise, and more accurate tools to pre-clinical cancer researchers worldwide. 👏 A huge congratulations to the R&D team led by Mike IRVINE and a big thank you to Innovate UK for their continued support. We look forward to working with our collaborators at NPL to drive the development of this exciting technology forward. #grateful #cancerresearch #innovation Find out more in the full announcement 👇 :
-
🌟 Congratulations to our portfolio company Verinnogen on its Innovate UK grant! The grant will support its collaboration with the National Physical Laboratory (NPL) to optimise its 3D surface profiling technology, designed to measure grafted tumours in preclinical cancer models more accurately, precisely, and quickly than traditional methods. Find out more below ⬇ #OnMyHorizon #Oncology Cancer Research Horizons
🎉 We are delighted to announce that Verinnogen has been successful in its application to Innovate UK’s Analysis for Innovators programme. After submitting our vision for key design areas within our novel tumour measuring tool, Innovate UK facilitated matchmaking with the world-leading National Physical Laboratory (NPL). Using their deep expertise, we will work together to optimize the optical configuration of this next generation tool, helping to bring fast, precise, and more accurate tools to pre-clinical cancer researchers worldwide. 👏 A huge congratulations to the R&D team led by Mike IRVINE and a big thank you to Innovate UK for their continued support. We look forward to working with our collaborators at NPL to drive the development of this exciting technology forward. #grateful #cancerresearch #innovation Find out more in the full announcement 👇 :
-
Entrepreneur-in-Residence at National Institutes of Health/NHLBI and BioHealth Innovation, Inc.
We are pleased to announce that Arnold Consultancy & Technology, LLC was recently awarded an NIH Small Business Innovation Research (SBIR) Phase I grant, funded by the National Cancer Institute, and entitled "ModEx, a cloud-based, centralized health economic model marketplace to reduce costs and enhance equity in cancer"! We will update you with information on abstracts and presentations as they occur.
-
🔬 Exciting News Alert! 🚀 Rosetta Omics, a cutting-edge deeptech startup revolutionizing oncology precision medicine, is thrilled to announce its membership and partnership with France Biotech At Rosetta Omics, our mission is clear: to leverage the power of AI and multiomics data to drive advancements in cancer treatment. With this new partnership with France Biotech, a leading voice in the French biotech ecosystem, we're poised to accelerate our impact and forge invaluable connections within the french healthcare industry. Joining France Biotech opens up a world of opportunities for collaboration, innovation, and growth. We're eager to collaborate with fellow trailblazers, access resources, and contribute to the vibrant biotech community in France and beyond. Our journey to transform oncology is fueled by a passionate team dedicated to making a difference in the lives of patients worldwide. Together with France Biotech, we're committed to driving forward the future of healthcare through groundbreaking research, technology, and partnerships. #RosettaOmics #FranceBiotech #Oncology #PrecisionMedicine #Biotech #Innovation #AI #multiomics #HealthcareRevolution 🧬💡
-
-
Exciting News from KIKK Capital II We are thrilled to announce our €2M Seed investment in Chromodynamics, an innovative deep-tech company revolutionizing biomedical research with its cutting-edge automated microscopy platform. Based at the High Tech Campus Eindhoven, Chromodynamics is tackling a critical unmet need in the biotech industry by enabling rapid and precise identification of cells in tissue samples. Their breakthrough technology will accelerate drug development (think immunotherapies for cancer!) and also holds the potential to transform personalized medicine in the long term. As a deep-tech investor with a strong track, we at KIKK Capital are excited to support Chromodynamics' mission. Congratulations to CEO Wouter Vijvers, CCO Caspar Pronk, and the entire Chromodynamics team for reaching this important milestone. We are proud to be part of your journey!
-
OncoBLAZE LLC, an innovative academic startup founded out of the Medical University of South Carolina (MUSC) and an Innosphere client company, has been awarded a $374,000 Phase I Small Business Technology Transfer (STTR) grant by The National Institutes of Health (NIH). This is the second STTR Phase I grant the company has secured within its first year, having previously received a grant from the National Science Foundation (NSF) earlier in 2024. This new funding will enable OncoBLAZE to conduct preclinical studies in rodent tumor models, further validating its cutting-edge cancer recurrence prevention technology. Read the full release here: https://lnkd.in/giE-g4Xu
-
-
Cancer is a scary word. Unfortunetely we're hearing the word more often. From friends, friends of friends, family and in the workplace. Globally an estimated 20 million new cases and 9.7 million deaths were reported in 2022 alone. At AIXCS, healthcare is one of core investment areas for us and it was a pleasure to see the recent successful seed funding round at a French start-up Spotlight Medical, leveraging AI to provide faster diagnosis and more effective individualized treatment. This would be a game-changer because not all treatments are created equal, and what works for one person might not work for another. By using AI to analyze mountains of patient data, Spotlight Medical can ensure that no one is over or undertreated, giving everyone the best chance at beating cancer. Read the full story at https://lnkd.in/dRmn2xYp To learn more about AIXCS, and join our venture pre-IPO whitelist visit https://www.aixcs.ai #AI #biotech #cancer #venturecapital #impact
-
-
𝐀𝐫𝐬𝐞𝐧𝐚𝐥 𝐁𝐢𝐨𝐬𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐑𝐚𝐢𝐬𝐞𝐬 $325𝐌 𝐢𝐧 𝐎𝐯𝐞𝐫𝐬𝐮𝐛𝐬𝐜𝐫𝐢𝐛𝐞𝐝 𝐒𝐞𝐫𝐢𝐞𝐬 𝐂 𝐭𝐨 𝐀𝐝𝐯𝐚𝐧𝐜𝐞 𝐂𝐀𝐑 𝐓-𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐟𝐨𝐫 𝐒𝐨𝐥𝐢𝐝 𝐓𝐮𝐦𝐨𝐫𝐬 Arsenal Biosciences has closed a $325 million Series C financing round. The round includes new investors like ARCH Venture Partners, Regeneron Ventures, and NVIDIA’s NVentures, along with continued support from Bristol-Myers Squibb and SoftBank Vision Fund 2. 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: • The funds will support the development of ArsenalBio’s CAR T-cell therapies for solid tumors, including ovarian, kidney, and prostate cancers. • ArsenalBio is using its advanced T-cell engineering platform to push innovation and tackle unmet needs in cancer treatment. • CEO Ken Drazan, M.D., said this funding will help scale manufacturing and explore new areas in T-cell medicine. ArsenalBio is working on next-generation T-cell therapies that use CRISPR technology for better tumor targeting and increased effectiveness. Follow us for updates on the latest biotech news in cancer research. #Biotech #CellTherapy #Oncology #CancerResearch #CAR_T
We are thrilled to enter this alliance with our sister institute Oncode Institute and Cancer Research Horizons!